Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection

J

Janssen (J&J Innovative Medicine)

Status

Conditions

HIV

Treatments

Drug: Rilpivirine Long Acting (RPV LA)

Study type

Expanded Access

Funder types

Industry

Identifiers

NCT03847376
TMC278LAHTX2001 (Other Identifier)
CR108331

Details and patient eligibility

About

The main purpose of this pre-approval access program (PAAP) is to provide rilpivirine Long Acting (RPV LA) injectable suspension for the treatment of human immunodeficiency virus (HIV)-1 infection as single patient request to individuals who have no available treatment alternatives and/or limited treatment options (for example, who are unable to participate in the Phase III clinical studies or do not qualify). RPV LA can only be provided if participants are also eligible for cabotegravir Long Acting injections.

Sex

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems